Insider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Sells 13,288 Shares of Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Michael A. Metzger sold 13,288 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the transaction, the chief executive officer now directly owns 300,121 shares of the company’s stock, valued at approximately $4,651,875.50. The trade was a 4.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Syndax Pharmaceuticals Stock Performance

SNDX stock traded down $0.15 during midday trading on Wednesday, reaching $14.86. 3,212,288 shares of the company were exchanged, compared to its average volume of 2,342,525. The stock’s 50-day simple moving average is $14.00 and its 200 day simple moving average is $17.27. Syndax Pharmaceuticals, Inc. has a 1-year low of $12.06 and a 1-year high of $25.34. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -4.09 and a beta of 0.90.

Analyst Ratings Changes

Several brokerages have commented on SNDX. Citigroup raised their price target on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, November 19th. The Goldman Sachs Group lifted their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Scotiabank cut their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. JPMorgan Chase & Co. lifted their price objective on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday, November 21st. Finally, HC Wainwright restated a “buy” rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $36.20.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Institutional investors have recently modified their holdings of the business. R Squared Ltd acquired a new stake in Syndax Pharmaceuticals during the 4th quarter worth $26,000. Values First Advisors Inc. purchased a new stake in shares of Syndax Pharmaceuticals in the third quarter valued at about $30,000. Quantbot Technologies LP purchased a new stake in shares of Syndax Pharmaceuticals in the third quarter valued at about $49,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after buying an additional 541 shares during the period. Finally, Cape Investment Advisory Inc. grew its holdings in shares of Syndax Pharmaceuticals by 157.1% during the fourth quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock worth $85,000 after buying an additional 3,927 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).